Company intelligence / Profile preview
FIMECS, Inc.
Fujisawa, Kanagawa, Japanfimecs.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Preclinical
01
Overview
FIMECS has developed a proprietary targeted protein degradation platform enabling the discovery of small molecule drugs against previously undruggable targets. Their lead program(s) are preclinical, with focus on oncology/immuno-oncology. The company was acquired by RaQualia Pharma in early 2024 to further leverage its technology for unmet medical needs.
- Therapeutic areas
- OncologyOther
- Modalities
- Small molecules (specifically proteolysis-targeting chimeras/PROTACs and targeted protein degraders)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Takeda Pharmaceutical Co., Ltd. – license agreement for use of IRAK-M and other assets since Feb.2018Academic collaboration with Kyoto University disclosed in September 2024 news release
Beyond the preview
Go deeper on FIMECS, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIMECS, Inc..